Michael Isaacson, MD
Cardiovascular Disease · Jonesboro, ARNPI 1972572097
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 269 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,639 and has fallen 98.0% since, to $32 in 2025.
Across 269 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$703
- Novartis$643
- Amgen$455
- Johnson & Johnson$410
- Boehringer Ingelheim$399
- Abbott$382
- plus $2K from 26 others
Across 41 payments — averaging $3072.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$53K
- CSL Behring$36K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$25K
- Amgen$11K
What the payments were for
- Food & beverage$4,76299%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 43 | $703 |
| Novartis | 41 | $643 |
| Amgen | 31 | $455 |
| Johnson & Johnson | 30 | $410 |
| Boehringer Ingelheim | 24 | $399 |
| Abbott | 13 | $382 |
| Merck | 18 | $293 |
| Daxor Corporation | 1 | $165 |
| E.r. Squibb & Sons, L.L.C. | 10 | $153 |
| Edwards Lifesciences | 1 | $148 |
| Sanofi-aventis U.S. LLC | 8 | $141 |
| Novo Nordisk | 6 | $137 |
| Bayer | 4 | $106 |
| AstraZeneca | 8 | $105 |
| Alnylam Pharmaceuticals Inc. | 4 | $65 |
| Scpharmaceuticals Inc. | 2 | $50 |
| Regeneron Healthcare Solutions, Inc. | 3 | $45 |
| Inspire Medical Systems, Inc. | 1 | $44 |
| Esperion Therapeutics, Inc. | 3 | $41 |
| Cvrx, Inc. | 2 | $39 |
| Boston Scientific | 3 | $38 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Lexicon Pharmaceuticals, Inc. | 2 | $32 |
| Angiodynamics, Inc. | 1 | $27 |
| Cordis US CORP. | 1 | $23 |
| Akcea Therapeutics, Inc. | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Cook Medical LLC | 1 | $14 |
| Atricure, Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $12 |
| Teleflex LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BVA-100$165
- SAPIEN 3 Ultra RESILIA$148
- MitraClip$100
How this compares
$4,786 in reported general payments places this provider in the 60th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 373 | $297,293 |
| EntrestoSacubitril/Valsartan | 87 | $76,132 |
| JardianceEmpagliflozin | 95 | $68,379 |
| Repatha SureclickEvolocumab | 72 | $52,668 |
| BrilintaTicagrelor | 41 | $19,834 |
| XareltoRivaroxaban | 19 | $11,540 |
| Praluent PenAlirocumab | 13 | $6,256 |
| Rosuvastatin Calcium | 460 | $4,996 |
| Ranolazine ErRanolazine | 30 | $3,931 |
| Amlodipine-AtorvastatinAmlodipine/Atorvastatin | 14 | $3,299 |
| Potassium Chloride | 157 | $2,654 |
| Ezetimibe | 140 | $2,567 |
| Flecainide Acetate | 69 | $2,402 |
| Metoprolol Succinate | 178 | $2,365 |
| Diltiazem 12hr ErDiltiazem Hcl | 14 | $1,964 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $703 | $297,293373 claims |
| NovartisEntresto | $643 | $76,13287 claims |
| Boehringer IngelheimJardiance | $399 | $68,37995 claims |
| AstraZenecaBrilinta | $105 | $19,83441 claims |
| Johnson & JohnsonXarelto | $410 | $11,54019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Jonesboro
- Barry TedderJonesboro$130K
- Maximiliano ArroyoJonesboro$46K
- Dharmendra PatelJonesboro$36K
- Nephertiti EfeovbokhanJonesboro$15K
- Matthew HausteinJonesboro$8K
- Anthony WhiteJonesboro$8K
- Jaime ChavezJonesboro$7K
- Mahesh AradhyaJonesboro$5K
- Ian CawichLittle Rock$294K
- Harvinder DodEl Dorado$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.